Brielle Benyon

September 23, 2022

From NFL Hall of Famer Shannon Sharpe and Monty Python member sharing their cancer diagnoses to “Good Morning America” promoting Be The Match, here’s what’s happening in the cancer space this week.

September 22, 2022

Patients with blood cancer who have higher levels of neurofilament light chains — which indicate brain injury — were found to be more likely to develop neurotoxicity after CAR-T cell therapy, according to recent research.

September 22, 2022

The Food and Drug Administration approved Retevmo for the treatment of patients with advanced or metastatic non-small cell lung cancer with a rearranged RET gene fusion.

September 21, 2022

Melanoma of the skin has been shown to be greatly associated with exposure to sunlight, whereas uveal melanoma — commonly known as cancer of the eye — is not.

September 21, 2022

The Food and Drug Administration approved Pedmark for the prevention of chemotherapy-induced hearing loss in pediatric patients with localized, nonmetastatic solid cancers.

September 20, 2022

The Food and Drug Administration granted a priority review for Tukysa plus Herceptin for patients with pretreated, metastatic colon cancer.

September 19, 2022

An expert explains how antibody drug conjugates work to treat cancer.

September 17, 2022

Black women were more likely to benefit from neoadjuvant endocrine therapy for early-stage breast cancer, however, their outcomes were inferior to White women when it came to late-stage disease, recent research showed.

September 16, 2022

Over the past five years, CAR-T cell therapy has improved outcomes for many patients with blood cancer. Here’s what patients need to know about the immune-based treatment.

September 16, 2022

From the delay of some health care services in the United Kingdom due to Queen Elizabeth II’s funeral to actor Ryan Reynolds broadcasting his colonoscopy — including the finding of a pre-cancerous polyp — here’s what’s happening in the cancer space this week.

September 16, 2022

Botensilimab will be evaluated in certain patients with colorectal cancer and melanoma, a type of skin cancer, in two recently launched clinical trials.

September 13, 2022

An expert discusses what patients need to know about the recent FDA approval of Enhertu for HER2-mutant non-small cell lung cancer, an aggressive subtype of the disease.

September 12, 2022

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.

September 09, 2022

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

September 09, 2022

The Food and Drug Administration issued a statement about the incidence of new cases of rare cancers that have occurred in the scar tissue around breast implants.

September 08, 2022

The first patient was treated in a phase 2 trial assessing the safety and efficacy of navicixizumab, with or without chemotherapy, in colorectal, gastric, ovarian and breast cancer.

September 07, 2022

Trodelvy bested chemotherapy for progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer.

September 06, 2022

Preparing for kidney cancer surgery encapsulates a full-body approach, which can help improve outcomes after the procedure.

September 03, 2022

Actress Jane Fonda announced that she has been diagnosed with non-Hodgkin lymphoma and will be receiving chemotherapy to treat the blood cancer.

September 02, 2022

The Food and Drug Administration approved Imfinzi plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer.

September 02, 2022

ATX01, a new topical treatment for chemotherapy-induced peripheral neuropathy, will be investigated in a phase 2 trial.

September 02, 2022

From “Good Morning America” host Robin Roberts stepping away from the show after her partner finished breast cancer radiation to a former Tampa Bay Buccaneer dying of leukemia, here is what’s happening in the cancer space this week.

August 31, 2022

Patients with blastic plasmacytoid dendritic cell neoplasms can enroll in the ongoing CADENZA trial, which is investigating the safety and efficacy of the novel agent pivekimab sunirine in patients with the rare blood cancer.

August 31, 2022

The FDA’s decision allows patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome — types of blood cancer — to continue enrolling on the TakeAim Leukemia trial.

August 31, 2022

Patients with early-stage rectal cancer may be able to forego major surgery — thus preserving their organs and quality of life — with a pre-surgical chemotherapy regimen, according to recent study results.

August 31, 2022

The first patient has been treated with H002, a novel drug being investigated for non-small cell lung cancer that is resistant to a prior EGFR TKI treatment.

August 30, 2022

An expert explains the different types of kidney cancer surgeries, and what patients can expect to experience after the procedure.

August 30, 2022

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

August 29, 2022

Firefighters and recovery workers exposed to the aftermath of 9/11 in New York City had a higher occurrence of MGUS, a condition which may progress to myeloma, according to recent research.

August 26, 2022

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement.